Since anti-MDA5 and anti-Ro-52 antibodies affect the response to treatment and prognosis in patients with DM-ILD, we examined whether there was any difference in IGFBP levels between patients tested positive and those tested negative for these antibodies. The gene discussed is TRIM21; the disease is dermatomyositis.